DE3585963D1 - Sulfonierte harze mit therapeutischer wirksamkeit, deren darstellung sowie diese enthaltende arzneimittel. - Google Patents

Sulfonierte harze mit therapeutischer wirksamkeit, deren darstellung sowie diese enthaltende arzneimittel.

Info

Publication number
DE3585963D1
DE3585963D1 DE8585102208T DE3585963T DE3585963D1 DE 3585963 D1 DE3585963 D1 DE 3585963D1 DE 8585102208 T DE8585102208 T DE 8585102208T DE 3585963 T DE3585963 T DE 3585963T DE 3585963 D1 DE3585963 D1 DE 3585963D1
Authority
DE
Germany
Prior art keywords
presentation
products containing
medicinal products
therapeutic effectiveness
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585102208T
Other languages
English (en)
Inventor
Elso Manghisi
Giuseppe Cascio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Luso Farmaco dItalia SpA
Original Assignee
Istituto Luso Farmaco dItalia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Luso Farmaco dItalia SpA filed Critical Istituto Luso Farmaco dItalia SpA
Application granted granted Critical
Publication of DE3585963D1 publication Critical patent/DE3585963D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE8585102208T 1984-03-09 1985-02-28 Sulfonierte harze mit therapeutischer wirksamkeit, deren darstellung sowie diese enthaltende arzneimittel. Expired - Lifetime DE3585963D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT19960/84A IT1175814B (it) 1984-03-09 1984-03-09 Resine solfoniche ad attivita' terapeutica,loro preparazione e composizioni farmaceutiche che le contengono

Publications (1)

Publication Number Publication Date
DE3585963D1 true DE3585963D1 (de) 1992-06-11

Family

ID=11162658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585102208T Expired - Lifetime DE3585963D1 (de) 1984-03-09 1985-02-28 Sulfonierte harze mit therapeutischer wirksamkeit, deren darstellung sowie diese enthaltende arzneimittel.

Country Status (8)

Country Link
US (1) US4587242A (de)
EP (1) EP0154895B1 (de)
JP (1) JPH0623104B2 (de)
AT (1) ATE75614T1 (de)
DE (1) DE3585963D1 (de)
ES (1) ES8700932A1 (de)
IT (1) IT1175814B (de)
ZA (1) ZA851611B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
FR2623714B1 (fr) * 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
US5008433A (en) * 1988-05-18 1991-04-16 Marion Laboratories, Inc. 2-hydroxy-3-(4-methoxyphenyl)-3-(2-aminophenylthio)propionic acid, 8'-phenylmenthyl ester, especially for diltiazem
DK0702009T3 (da) * 1994-09-16 1999-02-01 Orion Corp Fermion Fremgangsmåde til fremstilling af farmaceutisk aktive benzothiazepinderivater
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
JP2008546835A (ja) * 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム 複数の活性薬物−樹脂抱合体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB857194A (en) * 1957-07-05 1960-12-29 Clinical Products Ltd Therapeutic agents comprising ion-exchange resins
US3562257A (en) * 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives
BR6915295D0 (pt) * 1969-01-25 1973-04-12 Tanabe Seiyaku Co Indicador cronologico de evento em transmissao televisada
US4364928A (en) * 1979-10-23 1982-12-21 Roussel-Uclaf Novel salts of ion exchange resins of the acid type
US4369175A (en) * 1981-07-27 1983-01-18 Ciba-Geigy Corporation Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them
JPS5910512A (ja) * 1982-07-09 1984-01-20 Tanabe Seiyaku Co Ltd 徐放性マイクロカプセルおよびその製法

Also Published As

Publication number Publication date
ES8700932A1 (es) 1986-11-16
ATE75614T1 (de) 1992-05-15
ZA851611B (en) 1985-11-27
JPS60208918A (ja) 1985-10-21
IT8419960A0 (it) 1984-03-09
IT1175814B (it) 1987-07-15
EP0154895A2 (de) 1985-09-18
ES541089A0 (es) 1986-11-16
US4587242A (en) 1986-05-06
JPH0623104B2 (ja) 1994-03-30
EP0154895A3 (en) 1987-05-06
EP0154895B1 (de) 1992-05-06

Similar Documents

Publication Publication Date Title
GB8804164D0 (en) Bandage for administering physiologically active compound
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
ATE151285T1 (de) Orale arzneimittel mit kolonspezifischer freisetzung
MY102038A (en) 4-substituted androstendione derivatives and process for their preparation
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
DE3585963D1 (de) Sulfonierte harze mit therapeutischer wirksamkeit, deren darstellung sowie diese enthaltende arzneimittel.
AU555093B2 (en) Calcium-antagonist composition
NO870049L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
US4806530A (en) Pharmaceutical compositions based on diltiazem and lysine acetylsalicylate
HUT70033A (en) Process for producing synergetic pharmaceutical composition containing calcium channel blocking agent and calcium compound or vitamin d
DK694188D0 (da) Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel
IL85257A0 (en) Pharmaceutical compositions containing a certain benzothiazepine derivative having renal function-improving effect and diuretic effect
BR9710038A (pt) Novas composições e matrizes radiofarmacêuticas e seus usos.
IT9022340A0 (it) Processo per la preparazione del (+)-cis-3-(acetossi)-5-(2-(dimetilammino)etil)-2,3-diidro-2-(4-metossifenil)-1,5-benzotiazepin-4-(5h)-one cloridrato.
EP0246573A3 (en) Pharmaceutical composition containing a 8-chlorobenzothiazepine compound and its use
AR240017A1 (es) Procedimiento de preparacion de una composicion farmaceutica para absorcion percutanea.
FR2547730B1 (fr) Medicament hypolipidemiant contenant comme ingredient actif la d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one ou un de ses sels d'addition d'acides acceptables en pharmacie
IT8420148A0 (it) Procedimento per la preparazione del(+)-cis-5-[2-(dimetilamino)etil]-2,3-diidro-3-idrossi-2-(p-metossifenil)-1,5-benzotiazepin-4(5h)-one acetato cloridrato
KR890001536A (ko) 혈증 지질 조성을 개선시키기 위한 제약 조성물.
WO1991019499A1 (en) N-desmethyl - deacetyl diltiazem for use in reducing hypertension
KR920011495A (ko) 치료용 활성을 갖는 설폰산수지, 그것의 제제 및 그것을 함유한 약제 조성물
FR2568124B1 (fr) Medicament pour traiter les etats hypotrophiques par administrations d'aspartate d'arginine
IT8422701A0 (it) Procedimento per il recupero delcis(+)-3-acetilossi-5-[2-(dimetilammino)etil]-2,3-diidro-2-(4-metossifenil)-1,5-benzotiazepin-4-(5h)-one cloridrato
BR9908155A (pt) Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda
IT8521855A0 (it) Procedimento per il recupero delcis(+)-3-acetilossi-5-[2-(dimetilammino)etil]-2,3-diidro-2-(4-metossifenil)-1,5-benzotiazepin-4-(5h)-one cloridrato

Legal Events

Date Code Title Description
8364 No opposition during term of opposition